Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease - Summary - MDSpire

Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease

  • By

  • Zhengtai Sun

  • Yuting Liu

  • Lijuan Que

  • May 28, 2026

  • 0 min

Share

Objective:

To conduct a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database to evaluate the safety of perfluorohexyloctane ophthalmic solution in treating dry eye disease (DED).

Key Findings:
  • Verify that all findings are directly sourced from the data without added interpretation.
Interpretation:

Remove the statement regarding major safety concerns.

Limitations:
  • The study is based on spontaneous reporting, which may not capture all AEs.
  • Data may be influenced by reporting biases and underreporting of adverse events.
Conclusion:

Remove the suggestion for larger post-marketing studies.

Original Source(s)

Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease

  • by Zhengtai Sun, Yuting Liu, Lijuan Que

  • May 28, 2026

Related Content

Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.

Red Eye, Global Challenge

Narrative review calls for clearer guidance on noninfectious conjunctival hyperemia

  • March 18, 2026

  • 2 min
When Vision Fluctuates, Look to the Tear Film First

Dr. Theriot discusses the differences between natural tear film and artificial tears—and why the change in moniker to "lubricating drops" is appropriate.